This site is intended for U.S. healthcare professionals.

Experiencing Technical Difficulties

Translating mRNA
Educational Webinar Series

The Pfizer Vaccines US Medical Affairs Team invites you to join our Translating mRNA educational webinar series focused on COVID-19 and vaccination. The webinar series is designed to communicate scientific information on COVID-19, which may include recent study results to help inform healthcare providers regarding Pfizer and BioNTech COVID-19 vaccines. Please join us for our upcoming Translating mRNA webinar:

COVID-19 Updates from 2025 June ACIP meeting Thursday, July 24, 2025 @ 12:00 pm - 12:30 pm ET

Speaker:

Elizabeth A Thoburn, MPH

US Medical Director, Pfizer mRNA Vaccines Medical and Scientific Affairs

Register for Upcoming Webinar

First Name*Information Required

Last Name*Information Required

Email*Information Required

SpecialityOptional

Information Required
Information Required

This site is intended only for healthcare professionals in the United States. By clicking "Register", you confirm that you are a healthcare professional and that the information you have provided above is correct. You agree to Pfizer's processing of your personal data, in accordance with the Privacy Policy.

Live Webinar Link*

The webinar link will be live at 12:00 pm ET on July 24 th. If you would like to watch Prior Translating mRNA Webinar Webinar Recordings, they are available On-Demand

The webinar will include a live question-and-answer session with Pfizer medical experts.

Target Audience: US Healthcare professionals including physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.

Missed a Webinar? Prior Translating mRNA Webinar Recordings are Available On-Demand

Indication:

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Emergency Use Authorization:

Emergency uses of COVID-19 vaccines from BioNTech and Pfizer, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 6 months of age and older. Emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical products under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.